Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Vyome Holdings reported a net loss of $2.64 million for the nine months ended September 30, 2026, a significant improvement from the $9.20 million loss in the prior year period which was impacted by high transactional fees. The company strengthened its cash position to $6.96 million through ATM financing activities, while research and development expenses increased substantially to $1.58 million.
GCT Semiconductor reported Q3 2026 financial results with revenue increasing 148.6% year-over-year to $1.1 million. The company highlighted that year-to-date 5G chipset shipments exceeded 11,300 units and expanded its addressable market into terrestrial-based location services.
Term
Q3 2026
“We continued to make progress across our 5G customer programs in the third quarter, advancing integration and certification work with existing customers while expanding the range of applications our 5G chipsets can serve.”
Bally’s Chicago Operating Company entered into a Master Managed Technology Services Agreement and an Exclusive Neutral Host Lease Agreement with Tillman Digital Cities LLC. The agreements provide technology infrastructure and wireless connectivity for the company's permanent casino resort development in downtown Chicago. The 10-year agreements involve estimated annual payments of $8.4 million for infrastructure and approximately $1.1 million per year for monthly services.
Assembly Biosciences, Inc. is a non-accelerated filer and smaller reporting company focused on therapeutic product candidates, primarily through a collaboration with Gilead Sciences. As of September 30, 2026, the company remains pre-revenue and unprofitable, relying on third-party CROs and collaborators for clinical development and manufacturing.
Rocket Pharmaceuticals reported third quarter 2026 financial results, highlighting FDA alignment on the pivotal Phase 2 trial for RP-A501 in Danon disease with dosing completion expected by mid-2027. The company ended the quarter with $279.4 million in cash and investments, which is expected to fund operations into the third quarter of 2028.
Term
Q3 2026
“With FDA alignment on the pivotal RP-A501 trial in Danon disease, our priority is to complete dosing by mid-2027. We are also advancing our broader cardiovascular portfolio, with dosing initiated in the Phase 1 trial of RP-A701 for BAG3-DCM and continued FDA engagement on a potential pivotal study of RP-A601 in PKP2-ACM. Commercial readiness for KRESLADI and activation of our first Qualified Treatment Centers bring us closer to treating eligible children. Our financial resources and the additional flexibility provided by the Hercules facility support these priorities as we work toward our next clinical and commercial milestones.”
Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals
QXO, Inc. reported third quarter 2026 financial results, including net sales of $4.9 billion and an adjusted EBITDA of $557 million. The results reflect the integration of legacy Beacon, Kodiak, and TopBuild businesses, with management targeting $50 billion in annual revenue within the decade. Additionally, the Board of Directors authorized a new $500 million common stock repurchase program.
“Our organic daily revenue trends improved for the second consecutive quarter despite a soft construction market. Companywide pricing increased 2.2% year over year. We’re prioritizing higher-margin products; in Roofing and Waterproofing, complementary product sales grew 4.2%, and TRI-BUILT reached a record 10.6% of sales. Mechanical insulation distribution revenue grew 16%, supported by strong data center demand.”
Brad Jacobs, chairman and chief executive officer of QXO
“We’re on track to reach $4 billion in adjusted EBITDA by 2030 from the businesses we already own and $50 billion in annual revenue within the decade through organic growth and disciplined acquisitions.”
Brad Jacobs, chairman and chief executive officer of QXO
ARC Group Acquisition I Corp. reported a net income of $1,318,548 for the nine months ended September 30, 2026, primarily driven by $1,822,314 in interest income from its trust account. The company completed its initial public offering in May 2026, resulting in $122,572,314 held in trust and 12,075,000 Class A ordinary shares subject to possible redemption.
First Advantage M&A Deal with Silver Lake Group, L.L.C.
First Advantage Corporation announced the closing of a secondary offering of 15,000,000 shares of common stock by investment funds affiliated with Silver Lake Group. The company did not sell any shares and received no proceeds from the transaction, which served to facilitate the resale of shares by the selling stockholder. The offering closed on November 12, 2026, following the entry into an underwriting agreement with Barclays and J.P. Morgan.
NeoVolta reported financial results for the quarter ended September 30, 2026, showing a sequential revenue rebound to $2.8 million driven by its residential third-party ownership (TPO) platform. The company also highlighted a $116 million Master Purchase Agreement for utility-scale products and a strategic 9 GWh battery cell supply collaboration with SK On.
Equillium, Inc. reported a net loss of $4.6 million for the third quarter of 2026, with cash and cash equivalents increasing to $53.3 million as of September 30, 2026, following a private placement. Subsequent to the quarter-end, the company raised an additional $20.0 million in gross proceeds, which management believes will fund operations for at least the next 12 months.
FS KKR Capital Corp. announced that it will make investor presentations available on its website after the market close on November 12, 2026. The materials will be hosted on the company's investor relations page under the Events & Presentations section.
Weyerhaeuser Company filed a formal investor presentation outlining its strategic goals through 2030, including an accelerated growth strategy to add $1.5 billion of incremental Adjusted EBITDA. The presentation highlights long-term targets for its timberlands, wood products, and natural climate solutions businesses, as well as its capital allocation framework and sustainability goals.
XTI Aerospace reported total assets of $69.9 million as of September 30, 2026, a decrease from $81.2 million at year-end 2025, primarily driven by a reduction in cash and the disposal of its discontinued Inpixon Business. The company's balance sheet reflects significant liabilities including a $24.5 million warrant liability and the introduction of a $5.9 million asset-based revolving line of credit.
Arxis Insider Kevin Scott Perhamus Sells $1.27M of Stock
Kevin Scott Perhamus sold 25,000 shares of Arxis, Inc. at $50.59 to $51.19 a share (average $50.92) in 2 transactions, worth $1.27M in total on Nov 9, 2026. Shares held after the trade: 3,548,133 (-0.4%).
Paylocity Holding Insider Steven I. Sarowitz Sells $1.32M of Stock
Steven I. Sarowitz sold 7,300 shares of Paylocity Holding Corp at $180.14 to $181.16 a share (average $180.45) in 3 transactions, worth $1.32M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 4,341,095 (-0.0%).
Teva Pharmaceutical Industries EVP, Europe Commercial Richard Daniell Sells $1.93M of Stock
Richard Daniell, EVP, Europe Commercial, sold 45,003 shares of Teva Pharmaceutical Industries Ltd at $42.80 to $42.91 a share (average $42.86) in 2 transactions, worth $1.93M in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 55,755 (-26.4%).
Flowers Foods reported third quarter 2026 net sales of $1.169 billion, a 4.7% decrease year-over-year as favorable pricing was offset by lower volumes. Net income fell 63.6% to $14.4 million due to higher logistics costs and marketing investments, leading the company to lower its full-year 2026 financial guidance.
Term
12 weeks
“Our third-quarter results reflect a continued challenging operating environment, driven by pressure on household budgets, evolving consumer behavior and heightened promotional activity, as well as areas where we need to move faster with focused execution.”
Ryals McMullian, chairman and CEO of Flowers Foods
“While it will take time for our initiatives to translate more fully into results, we believe they are putting Flowers on a stronger path forward. We expect the environment to remain challenging in the near term, but we remain confident in the long-term potential of the business.”
Ryals McMullian, chairman and CEO of Flowers Foods
Immix Biopharma reported its Q3 2026 operational progress, highlighting an 89% complete response rate in its NEXICART-2 clinical trial for NXC-201. The company strengthened its leadership team with new SVPs of Technical Operations and Regulatory Affairs as it prepares for a planned BLA submission in mid-2027.
BlossomHill Therapeutics reported third quarter 2026 financial results, ending the period with $224.9 million in cash and cash equivalents. The company aligned with the FDA on a Phase 2 dose for BH-30643 and plans to initiate the pivotal SOLARA-2 trial in Q1 2027 for patients with EGFR C797S-positive NSCLC.
Term
Q3 2026
“We are pleased to have aligned with the FDA on a recommended Phase 2 dose of 50 mg BID based on favorable PK, safety and efficacy data in the Phase 1 portion of the SOLARA trial. We are now preparing to initiate SOLARA-2, a single arm, pivotal Phase 2 trial designed to evaluate BH-30643 in both chemotherapy-naive and chemotherapy-pretreated patients with C797S-positive NSCLC after progression on a third-generation EGFR TKI.”
J. Jean Cui, Ph.D., Founder, President and Chief Executive Officer
Azitra, Inc. reported Q3 2026 financial results and provided updates on its dermatology pipeline, including positive ex vivo results for its ATR-COSF cosmetic program and the advancement of ATR-04 into Cohort 2 of its Phase 1/2 trial. The company highlighted that upcoming clinical data readouts could trigger an additional $5.25 million to $10.5 million in investment from existing institutional investors.
Term
Q3 2026
“During the third quarter and recent weeks, we made substantial progress with our two priority programs, generating encouraging results for ATR-COSF and advancing ATR-04 forward in the clinic while broadening its potential to benefit more patients.”
Francisco Salva, Chief Executive Officer
“The remainder of 2026 has the potential to be a defining period for Azitra as we expect to report initial results from our first in-human cosmetic study of ATR-COSF and topline data from Cohort 1 of our ATR-04 Phase 1/2 trial.”
Crescent Biopharma reported Q3 2026 financial results and provided clinical updates on its lead programs, including the completion of dose escalation for CR-001 in the Phase 1/2 ASCEND trial. The company expects initial monotherapy data for CR-001 in Q1 2027 and highlighted that over 2,000 patients are expected to be dosed across its portfolio by mid-2027.
Counterparty
Kelun-Biotech
“This has been a defining year for Crescent. We advanced three programs into the clinic and established a leading position in developing next generation IO and ADC combinations which we believe have the potential to redefine cancer care. Together with our partner Kelun-Biotech, we have achieved a remarkable nine IND clearances, and anticipate that more than 2,000 patients will be dosed across our portfolio by mid-2027.”
Joshua Brumm, chief executive officer of Crescent
“The team’s strong execution has positioned us for several meaningful clinical data readouts in 2027, beginning in the first quarter with monotherapy results from our global ASCEND trial of CR-001, including first-line NSCLC patients, followed by initial standard of care chemotherapy combination data from multiple tumor types.”
KinderCare Learning Companies reported third quarter 2026 revenue of $665.3 million, a 1.7% decrease year-over-year, and a net loss of $85.0 million. The results were impacted by lower enrollment at early childhood education centers and $83.4 million in impairment losses related to market capitalization declines and center closures.
“While third-quarter enrollment at KinderCare Learning Centers fell short of our expectations, recent improvements reinforce our confidence in the operational changes we've made.”
Tom Wyatt, Chairman and Chief Executive Officer
“We know families face tough financial choices, and we’re focused on demonstrating the value of KinderCare’s high-quality education and care across all of our brands.”
Horizon Kinetics Holding Corp reported Q3 2026 financial results, including a net loss of $18.4 million primarily driven by unrealized declines in the fair value of key investment holdings. Despite the quarterly loss, year-to-date net income remains positive at $35.8 million, and the company's Board authorized a new $25 million share repurchase program and declared a $0.13 per share dividend.
Mid-America Apartments $350M Debt Financing with U.S. Bank Trust Company, National Association
Mid-America Apartments, L.P. completed the issuance and sale of $350 million in 5.350% Senior Notes due 2031. The notes were issued under an eleventh supplemental indenture with U.S. Bank Trust Company as trustee and will pay interest semi-annually starting June 2027.
Rekor Systems, Inc. reported a decrease in revenue to $10.9 million for the quarter ended September 30, 2026, compared to $14.2 million in the prior year. Despite the revenue decline, the company significantly reduced its net loss to $2.9 million for the quarter, aided by a $3.9 million gain on lease remeasurement and lower overall operating expenses.
Bentley Systems Insider Keith A. Bentley Sells $4.52M of Stock
Keith A. Bentley sold 100,000 shares of Bentley Systems Inc at $45.18 a share, worth $4.52M in total on Nov 10, 2026. Shares held after the trade: 3,745,254 (-2.6%).
TransMedics Group Director James R. Tobin Sells $380K of Stock
James R. Tobin, Director, sold 4,000 shares of TransMedics Group, Inc. at $94.98 a share, worth $380K in total on Nov 9, 2026. Shares held after the trade: 2,922 (-57.8%).
Intellicheck, Inc. reported a net income of $1.77 million for the nine months ended September 30, 2026, a significant improvement from a net loss of $279,000 in the prior year period. Total revenues grew to $17.2 million for the nine-month period, and the company maintained a strong liquidity position with $13.17 million in cash and cash equivalents.
Merlin, Inc. reported Q3 2026 revenue of $3.5 million and GAAP net income of $73.8 million, a significant shift from the prior quarter's loss. The company highlighted new contract wins with USSOCOM and USAFRICOM and stated its 2027 plan aims to reduce operating expenses to extend its cash runway into 2029.
Term
Q3 2026
“The new $8.9 million task order with USSOCOM moves our C-130J autonomy program into its integration phase, laying the groundwork for future flight demonstrations and production revenue with SOCOM and ultimately the global C-130J fleet including hundreds of aircraft.”
Matt George, CEO of Merlin
“the goal of our planning process is to ensure that we not only meet the opportunities presented by our current contracts, but also the broader market potential we detailed on last quarter’s call. We believe that it is imperative for Merlin to continue to advance the Merlin Pilot, but it is also imperative that we demonstrate discipline in the investments we make along the way.”
LGAM Private Credit LLC reported total investment income of $12.3 million for the quarter ended September 30, 2026, and net investment income of $5.4 million. The company's net asset value per unit decreased to $19.35 from $19.93 at the end of 2025, primarily driven by $6.5 million in net unrealized depreciation on investments during the first nine months of the year.